BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 20579215)

  • 1. Pharmacotherapy of cholestatic liver diseases.
    Paumgartner G
    J Dig Dis; 2010 Jun; 11(3):119-25. PubMed ID: 20579215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of cholestatic liver diseases].
    Gatzen M; Pausch J
    Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Molecular mechanisms of bile formation and cholestatic diseases].
    Poupon R
    Bull Acad Natl Med; 2003; 187(7):1261-74; discussion 1274-6. PubMed ID: 15146603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.
    Beuers U
    Nat Clin Pract Gastroenterol Hepatol; 2006 Jun; 3(6):318-28. PubMed ID: 16741551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cholestatic liver diseases].
    Reichel C; Meier-Abt PJ
    Ther Umsch; 1997 Nov; 54(11):639-44. PubMed ID: 9454366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2
    Hatano R; Kawaguchi K; Togashi F; Sugata M; Masuda S; Asano S
    Biol Pharm Bull; 2017; 40(1):34-42. PubMed ID: 28049946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets.
    Paumgartner G
    World J Gastroenterol; 2006 Jul; 12(28):4445-51. PubMed ID: 16874853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
    Lirussi F; Okolicsanyi L
    Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
    Paumgartner G; Beuers U
    Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
    Pusl T; Beuers U
    World J Gastroenterol; 2006 Jun; 12(22):3487-95. PubMed ID: 16773706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary biliary cirrhosis in adults.
    Momah N; Lindor KD
    Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):427-33. PubMed ID: 24580040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of cholestatic disease in 2017.
    de Vries E; Beuers U
    Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel and emerging therapies for cholestatic liver diseases.
    Goldstein J; Levy C
    Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choleretic effects of ursodeoxycholic acid on experimentally-induced intrahepatic cholestasis.
    Mizoguchi Y; Miyajima K; Kioka K; Seki S; Kobayashi K; Morisawa S
    Osaka City Med J; 1989 Nov; 35(2):83-91. PubMed ID: 2628845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The challenges of primary biliary cholangitis: What is new and what needs to be done.
    Terziroli Beretta-Piccoli B; Mieli-Vergani G; Vergani D; Vierling JM; Adams D; Alpini G; Banales JM; Beuers U; Björnsson E; Bowlus C; Carbone M; Chazouillères O; Dalekos G; De Gottardi A; Harada K; Hirschfield G; Invernizzi P; Jones D; Krawitt E; Lanzavecchia A; Lian ZX; Ma X; Manns M; Mavilio D; Quigley EM; Sallusto F; Shimoda S; Strazzabosco M; Swain M; Tanaka A; Trauner M; Tsuneyama K; Zigmond E; Gershwin ME
    J Autoimmun; 2019 Dec; 105():102328. PubMed ID: 31548157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases.
    Trauner M; Graziadei IW
    Aliment Pharmacol Ther; 1999 Aug; 13(8):979-96. PubMed ID: 10468672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
    Trauner M; Fickert P; Halilbasic E; Moustafa T
    Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
    Stiehl A; Rudolph G; Sauer P; Theilmann L
    J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term response of primary biliary cirrhosis (stage I) to therapy with ursodeoxycholic acid.
    Tromm A; May B; Klein CG; Klein R; Fisseler-Eckhoff A; Griga T
    Hepatogastroenterology; 2005; 52(63):753-6. PubMed ID: 15966198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary biliary cirrhosis and bile acids.
    Corpechot C
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S13-20. PubMed ID: 23141888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.